知镜 Cognispect · 医学文献与研究工作台

Treatment of Progressive Multifocal Leukoencephalopathy With Third-Party Allogeneic BK Virus T Cells.

Olson A, Li Y, Marin D, Thall PF, Bassett RL, Barnett M, Basar R, Banerjee PP, Kleiman TA, Chen M, Rexer J, Wintermark M, Choi J, Learned K, Kaur I, Sylejmani M, Abueg G, Chemaly RF, Mulanovich V, Shrestha R, Uprety N, Castro KM, Daher M, Galvan IM, Washington D, Champlin RE, Shpall EJ, Rezvani K.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026-10-01 · PMID 42402341

文献摘要

Background Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease caused by JC polyomavirus that affects immunosuppressed individuals and has no approved therapy. Here, we evaluate the safety and efficacy of third-party, off-the-shelf, partially HLA-matched BK virus-specific T cells (BK-VST) in patients with PML. Methods We conducted a single-center phase 2 study (including 3 patients treated under compassionate or emergency, INDs); 37 patients received most closely HLA-matched BK-VST at a median dose of 2.0 × 105 T cells/kg, with additional infusions permitted for subjects who did not achieve a complete response (CR). Twenty-three patients had an underlying diagnosis of hematologic malignancy. Each patient received a median of 2 doses (range, 1-12; IQR 2). Overall response (OR) was defined as virologic response with neurologic stabilization or improvement. Results During 12 months of follow-up, 21 patients (56.8%) achieved an OR, including 16 (43.2%) with a CR or CR with neurologic sequelae (CRnesq). Responses were rapid (median 23 days) and durable, with no loss of response observed despite limited HLA matching. The 1-year overall survival was 61.1% (95% CI, 41.9-77.4). Patients achieving an OR after the first infusion had markedly improved 1-year survival compared with nonresponders (93.3% vs 0%; P Conclusions These data demonstrate that third-party BK-VST infusions are safe and potentially effective, supporting a scalable immunotherapeutic approach for this otherwise fatal disease. Clinical Trials Registration. NCT02479698.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。